Dehinel Plus

Quick links to important sections

Dehinel Plus

Method of action: Anthelmintic

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dehinel Plus

Property Description
Active Ingredients Febantel, Praziquantel, Pyrantel (as embonate/pamoate)
Form Solid Dosage Tablet
Pharmacological Class Anthelmintic (Antiparasitic Agent)
Target Audience Dogs (including puppies)
Origin Synthetic
Manufacturer KRKA d.d. (Slovenia)

What is the Pharmacological Identity of Dehinel Plus?

Dehinel Plus is a prominent, synthetic veterinary medicinal product manufactured by KRKA d.d., defined as a broad-spectrum anthelmintic designed for use in dogs. Classified generally as an antiparasitic agent, it is specifically a combined-action drug because its therapeutic strength is derived from the synergistic function of its three distinct active ingredients. The medicine is supplied as a solid dosage tablet, a common form utilized for oral administration of anthelmintics. The formulation is clinically recognized for its essential role in preventing and managing common parasitic infections in the target species.

Composition: The Role of Febantel, Praziquantel, and Pyrantel

The efficacy of Dehinel Plus is built upon the synthetic triad of Febantel, Praziquantel, and Pyrantel (used as the embonate or pamoate salt). These components, belonging to different pharmacological groups, ensure that the medicine attacks intestinal parasites through multiple, complementary pathways. For instance, Praziquantel is recognized for its high efficacy against cestodes, which are tapeworms. Concurrently, the Febantel pro-drug and Pyrantel component ensure comprehensive action against nematodes, such as roundworms and hookworms, by targeting their cellular and neuromuscular systems.

General Purpose and Spectrum of the Triple Combination

The primary purpose of this triple combination is the effective elimination of intestinal parasitic worms, specifically designed to address mixed infestations. The formulation’s broad spectrum of activity is necessary to ensure concurrent action against both major groups of parasitic helminths: cestodes and nematodes. This multi-modal approach is a foundational principle of veterinary pharmacology for maximizing therapeutic success and mitigating the risk of incomplete parasite clearance. The overall benefit is a robust, single-product solution that provides comprehensive intestinal cleansing from specified internal parasites.

What side effects are possible with Dehinel Plus?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and regulatory safety limitations for Dehinel Plus, based on authoritative government regulatory sources. This information is descriptive and non-advisory.

Adverse Reactions by Frequency and System-Organ Class

The vast majority of adverse reactions reported are rare and affect the gastrointestinal system. The frequency classifications used are based on international regulatory standards.

Classification Adverse Reaction Population Note
Rare Transient loose faeces, diarrhea, and/or vomiting Observed in some puppies
Very Rare Vomiting (with or without diarrhea) Observed in adult dogs

Regulatory Safety Restrictions and Limitations

The official labeling includes specific contraindications and safety constraints necessary for safe use:

  • Hypersensitivity: The product is contraindicated in animals with a known hypersensitivity to the active ingredients (Praziquantel, Pyrantel embonate, Febantel) or to any of the excipients.
  • Drug Interactions: Must not be used simultaneously with piperazine compounds, as this can lead to an antagonistic effect (reduced efficacy). Caution is also required when using concurrently with other cholinergic compounds due to potential for toxicity.
  • Pregnancy and Pediatrics: Use is contraindicated during the first two-thirds of pregnancy. The product must not be used in dogs younger than 2 weeks of age or weighing less than 2 kg.
  • Lactation: The product may be used during lactation.

Note: If any serious adverse effects are observed, the veterinary surgeon should be informed. Accidental ingestion by a human requires immediate medical attention.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

This section is based exclusively on the Summary of Product Characteristics (SPC) and safety data documented by government regulatory authorities for medicinal products containing the active ingredients Febantel, Praziquantel, and Pyrantel (embonate/pamoate).

Documented Overdose Findings

Entity Regulatory Statement
Clinical Manifestation Vomiting has been observed, occurring only occasionally.
Exposure Threshold The symptom was documented following administration of a single dose of 5 times the recommended dose or greater.
Severe Outcomes The product is officially described as well tolerated in dogs; no severe or life-threatening systemic effects are explicitly listed in the overdose section.
Target Population Overdose findings are documented generally for dogs.

Regulatory Action Requirements

Entity Regulatory Statement
Required Emergency Actions No mandatory actions (e.g., "seek immediate medical attention") are explicitly stated in the official overdose documentation for the observed symptoms.
Supportive Measures No specific procedural steps (e.g., gastric lavage, activated charcoal) or instructions for symptomatic treatment are explicitly detailed in the official regulatory documentation.
Antidote or Monitoring The official documentation does not reference a specific antidote or specify mandatory hospital monitoring requirements.

The regulatory profile is constrained by the finding that the combination of active substances is well tolerated, even at five times the recommended dose. Because only occasional vomiting is documented, the official labeling does not contain explicit requirements for when urgent medical help must be sought or for specific overdose management procedures.

Therapeutic Uses of Dehinel Plus

Targeting Acute Symptomatic Discomfort

This medicine is applied across domains where additional symptomatic support is needed, primarily for animals experiencing symptoms related to systemic imbalance caused by internal parasites. The product is applied in addressing conditions when symptoms intensify and supportive relief is needed against a broad spectrum of gastrointestinal worms.


Addressing Fluctuating or Episodic Symptom Patterns

This treatment is relevant in conditions characterized by periods of heightened symptoms linked to a comprehensive range of parasites, including roundworm, hookworm, whipworm, and tapeworm infestations. It is applicable in scenarios where additional management of discomfort is required to support the animal during difficult episodes by easing distress.

“Applied in contexts marked by increased discomfort or tension, this medicine may assist with maintaining functional stability.”


Support for Symptom Clusters Requiring Management

Dehinel Plus is commonly used to help with groups of symptoms that may appear suddenly or intensify over time when an animal is affected by conditions involving episodic or fluctuating manifestations. It provides symptomatic relief that may help maintain a sense of stability when symptoms that create noticeable physiological strain become more noticeable, supporting general well-being during symptomatic phases.

Quick Fact: Relief for Symptoms Related to Systemic Imbalance

Regulatory References

  1. Irish Health Products Regulatory Authority Summary of Product Characteristics

Eligibility and Restrictions for Use

Official Eligibility Status for Dehinel Plus

The use of Dehinel Plus is strictly governed by population eligibility rules found in official regulatory labeling. The medicine is primarily indicated for use in dogs, including adult dogs and nursing bitches.

Contraindicated Populations (Must Not Use):

  • Hypersensitivity: Animals with a known sensitivity to any of the active substances (Praziquantel, Pyrantel, Febantel) or excipients.
  • Species: Cats and other non-target species.
  • Concomitant Use: Animals currently being administered piperazine compounds, due to risk of antagonistic effects.
  • Pregnancy: US regulatory labeling may state "DO NOT USE IN PREGNANT ANIMALS."

Age and Weight Restrictions:

  • Puppies: Prohibited in puppies under 3 weeks of age.
  • Weight: Prohibited for dogs weighing less than the regulatory threshold of 2.0 kg (approx. 4.4 lbs).

Conditional Use Status (EU Labeling):

  • Early Pregnancy: The product is not recommended for bitches during the first 4 weeks of pregnancy.
  • Later Pregnancy: Use is conditional and must be in accordance with a veterinary benefit/risk assessment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Dehinel Plus (containing Praziquantel, Pyrantel embonate, and Febantel) as established in government regulatory labeling.


Formal Interaction Restrictions

Interaction Type Interacting Substance Regulatory Outcome Constraint
Contraindicated Piperazine preparations Antagonism of anthelmintic effects. Do not use simultaneously
Pharmacodynamic Other cholinergic compounds Potential for increased systemic toxicity. Use with caution

Official Interaction Statements

The regulatory profile formally contraindicates the simultaneous use of Dehinel Plus with piperazine preparations. This restriction is required because co-administration leads to a pharmacodynamic antagonism that reduces the efficacy of the product's anthelmintic action, specifically concerning the Pyrantel component. Therefore, these substances must not be used simultaneously.

In addition to the piperazine restriction, the official labeling documents that concurrent use with other cholinergic compounds can result in an increased risk of systemic toxicity. The regulatory information also confirms that administration of the tablet is permissible with or disguised in food, indicating that no restrictive drug-food interaction is documented or requires fasting.

Mechanism of Action

Mechanism of Action

Dehinel Plus exerts its effect through a complementary, multi-modal pharmacodynamic action involving three components. The drug induces dual neuromuscular paralysis via Pyrantel and Praziquantel. Pyrantel acts as an agonist on parasite nicotinic acetylcholine receptors (nAChRs), causing prolonged muscle depolarization and spastic paralysis. Concurrently, Praziquantel modulates Ca^2+ ion homeostasis, driving uncontrolled calcium influx, which results in rapid tetanic contraction and structural damage to the parasite's outer layer.

This rapid action is combined with metabolic and structural collapse mediated by Febantel's active metabolites. These compounds bind specifically to parasite beta-tubulin, inhibiting microtubule formation and disrupting essential cellular structures. This systemic structural damage leads directly to failure in glucose uptake and nutrient transport, resulting in ATP depletion and eventual energy exhaustion, leading to parasite death via functional starvation. This multi-modal approach targets both motility and core viability, supporting the comprehensive efficiency of parasite elimination.

Dosage and Administration Information

Instruction Map: How to use Dehinel Plus — Official Administration Guidelines

This map formalizes the administration guidelines for Dehinel Plus tablets.


Administration Scope

Property Official Instruction
Route of Administration The product is authorized for oral use.
Dosing Schedule The base dosing rate is defined by body weight, requiring 15 mg/kg Febantel, 14.4 mg/kg Pyrantel, and 5 mg/kg Praziquantel. This rate corresponds to 1 standard tablet per 10 kg or 1 XL tablet per 35 kg body weight.
Timing in Relation to Meals (if applicable) Administration may occur with or without food; access to food is not restricted before or after the dose.
Preparation Requirements (if applicable) To ensure accurate dosing, both standard and XL tablets are approved for division into equal halves or quarters, depending on the strength and required fraction.
Age-Group Administration Rules Use is subject to minimum physical thresholds: not for dogs younger than 2 weeks of age and/or weighing less than 2 kg. Puppies are often scheduled for dosing from 2 weeks of age and every two weeks until 12 weeks of age.
Frequency Pattern Intermittent use is specified, ranging from a routine adult schedule of every 3 months to more frequent cycles for high-burden cases or specific life stages.

Connection to the Overall Use Protocol

The administration protocol is standardized around the principle of accurate weight-based dosing and intermittent cyclic scheduling. These instructions govern how the correct minimum effective dose is delivered orally and define the intervals for both routine control and more intensive treatment cycles. The flexibility to administer the tablet with food simplifies the required procedural steps, while the capability to divide the solid dosage form ensures precise adherence to the weight-based dosing formula across the entire approved target population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dehinel Plus


Evidence for Use in Mixed Infestations of Intestinal Worms

Research examining the combination of active ingredients in Dehinel Plus has primarily utilized controlled laboratory efficacy studies and clinical field trials. These studies were conducted to investigate the activity of the combination, and research explored the management of mixed infestations involving both major types of parasitic intestinal worms: Nematodes (such as roundworms and hookworms) and Cestodes (tapeworms).

In these trials, research monitored outcomes that included the Faecal Egg Count (FEC)—a measurement taken from stool samples—and, in highly controlled settings, the direct counting of recovered worms at the study's conclusion. The populations studied involved dogs of various breeds and ages, including dogs who had natural infections. These types of research efforts contribute to understanding symptom patterns and how parasitic load changes during the study period.

The Role of Controlled and Randomized Clinical Trials

The evidence base includes rigorous trial designs, such as Randomized Controlled Trials (RCTs), which are used to compare the outcomes of different treatment protocols. These studies monitored physiological strain or stress and collected data on specific outcomes, including physiological changes and tolerance. Findings describe patterns observed in the studies related to intestinal parasitic load. However, some of the field research cited in regulatory documents utilized designs that were non-blinded or non-controlled.


Evidence for Related Parasite Contexts Studied

Beyond the core anti-worm application, research has also explored the use of the combination in managing other parasitic challenges, such as protozoan infections (Giardiasis). This secondary research was evaluated in prospective trials and RCTs comparing protocols of varying lengths.

In studies exploring this context, researchers monitored outcomes by testing faecal samples for the presence of Giardia cysts and antigens. Findings were mixed, with studies reporting measurements for cyst detection that varied depending on the duration of the treatment course used in the protocol. Research highlights changes measured during the study period, particularly in faecal consistency, which is an outcome related to physical discomfort.


Long-Term Studies and Follow-Up Duration

Studies primarily focusing on the medicine's regulatory approval utilized short-term efficacy assessments, typically with follow-up durations limited to approximately seven to fourteen days post-treatment for faecal measurements. While research provides insight into short-term changes, long-term effects are not fully established. There is limited information for long-term outcomes, meaning the durability of the observed findings or the patterns of recurring infection over extended periods are not well characterized by the core research.

Key Studies & References

  1. Irish Health Products Regulatory Authority Summary of Product Characteristics for Dehinel Plus

Frequently Asked Questions (FAQ)

Common questions about Dehinel Plus (FAQ)


Q: Is Dehinel Plus a dewormer or something else?

A: Dehinel Plus is officially classified as an anthelmintic, which is a type of broad-spectrum dewormer specifically for dogs. According to regulatory documents, its primary purpose is to treat mixed infestations of common intestinal parasites, including both roundworms and tapeworms.


Q: Are there different versions of Dehinel Plus, and what's the difference?

A: Official product information references both a standard tablet and an XL tablet format. The difference is mainly in the concentration of the active ingredients within each tablet. This variance provides options for weight-based administration across dogs of varying sizes, particularly larger ones.


Q: Are there any human safety concerns when handling Dehinel Plus?

A: Official labeling includes precautions for the user. Regulatory documents state that individuals should wash their hands thoroughly after handling the product. In the event of accidental ingestion by a human, immediate medical advice should be sought.


Q: Can Dehinel Plus be crushed and mixed with food?

A: Regulatory documents indicate that the tablets can be administered directly or disguised in food to facilitate administration. Furthermore, tablets can be divided (e.g., halved or quartered) for accurate dosing. However, the regulatory information does not explicitly provide instructions regarding crushing the tablet.


Q: What's the difference between Dehinel Plus and a broad-spectrum dewormer?

A: Dehinel Plus is a broad-spectrum anthelmintic. This classification means it has a wide range of activity against the two major groups of intestinal parasites: nematodes (roundworms and hookworms) and cestodes (tapeworms). The combination of three active ingredients is intended to provide a comprehensive spectrum of action.


Q: Does Dehinel Plus treat heartworms?

A: No. The product is indicated for the treatment of mixed infestations of common intestinal roundworms and tapeworms only. Official documentation does not list heartworms (Dirofilaria immitis) in the product's spectrum of activity.


Q: Can Dehinel Plus be used for prevention or just for treatment?

A: The official dosing schedule specifies intermittent use for routine control—for example, administration every three months. This regular schedule is intended for routine control of parasitic infections, rather than being solely for acute treatment.


Q: What is the shelf life of Dehinel Plus tablets?

A: The shelf life of the product is officially indicated by the expiry date printed on the packaging and label. As long as the product is stored according to the instructions (i.e., out of sight and reach of children), it remains stable up to this date.


Q: Is Dehinel Plus effective against all stages of the worm lifecycle?

A: The product is indicated to be effective against certain developmental stages of the target parasites. This includes the mature and immature stages of specific roundworms, and the mature and larval stages of certain tapeworms. The full lifecycle stages that are affected can vary by specific parasite.


Q: Is Dehinel Plus safe for older, senior dogs?

A: Official regulatory documents do not list advanced age as a specific contraindication or restriction for the use of Dehinel Plus. Safety restrictions apply only to very young dogs, specifically those under two weeks of age or weighing less than 2 kg.


Q: Can a pet overdose on Dehinel Plus, and what would the signs be?

A: Safety studies documented in regulatory sources show the product is generally well tolerated, even at high doses. In some toxicity studies, a single dose up to five times the recommended amount occasionally resulted in an adverse effect, specifically vomiting.


Q: Why do vets recommend regular deworming with products like Dehinel Plus?

A: Regulatory information indicates the product is for the routine control of intestinal parasites. Beyond the pet's health, warnings note that certain tapeworm species (e.g., Echinococcus) pose a potential hazard to human health. Regular control is intended to manage the prevalence of these infections, including those with public health relevance.


Q: Does Dehinel Plus treat any external parasites?

A: No. The indications listed in official product information are specifically for the treatment of gastrointestinal (intestinal) roundworms and tapeworms. It is not indicated for treating external parasites such as fleas or ticks.


Q: Can Dehinel Plus cause a temporary change in appetite?

A: The adverse reactions reported in regulatory documents are mainly rare and affect the gastrointestinal system, such as vomiting, loose faeces, and diarrhea. A temporary change in appetite is not explicitly listed, but these GI-related side effects could potentially influence a dog’s desire to eat.


Q: Does Dehinel Plus cause a change in the color or consistency of the pet's stool?

A: Official adverse reaction reporting lists transient loose faeces and diarrhea as rare side effects, which are changes in stool consistency. No specific changes in stool color are mentioned in the regulatory documentation.


Q: Is there any evidence on Dehinel Plus's use in unusual pets (e.g., rabbits)?

A: The official documentation states the product is indicated for use only in dogs. Use in non-target species is generally contraindicated.


Q: How is the safety profile of Dehinel Plus established in clinical studies?

A: The safety profile is established through controlled, non-clinical studies such as toxicity and tolerance tests. These studies are conducted to observe the safety margins and to monitor the potential occurrence and incidence of adverse reactions at both recommended and elevated doses in the target species.


Q: Is Dehinel Plus the same as other deworming tablets like Drontal or Cestem?

A: Dehinel Plus contains a specific combination of Praziquantel, Pyrantel embonate, and Febantel. Other registered products that contain this exact combination of active ingredients are considered to be therapeutic equivalents in terms of their intended action against the parasites.


Q: How do I know if my dog needs Dehinel Plus?

A: Regulatory use directions state that the product is used either to treat an existing infection that has been confirmed by a laboratory fecal examination or is administered as part of a routine, regular parasite control schedule.


Q: What's the main benefit of using a combination drug like Dehinel Plus?

A: The main benefit of this product is the broad spectrum of activity resulting from its three active ingredients. This combination is designed to provide effective control against both major types of parasites—roundworms and tapeworms—through a single product.


Q: Is it normal to see worms in the stool after giving Dehinel Plus?

A: The active ingredients work by paralyzing and disintegrating the parasites within the intestines. Regulatory information notes that for tapeworms, it is rare to see whole worms passed. Instead, owners may occasionally observe only disintegrated and partially digested pieces in the stool.


Q: What are the most common side effects people see with Dehinel Plus?

A: Official regulatory documents list adverse reactions as rare or very rare, primarily affecting the gastrointestinal tract. These reactions include transient loose faeces, diarrhea, and/or vomiting. These effects are usually mild and temporary.


Q: How often should a pet typically be given Dehinel Plus?

A: Official regulatory information specifies intermittent use for routine control. While the frequency can vary based on individual risk and parasite burden, a common routine adult schedule often involves dosing every three months.


Q: Is it okay to give Dehinel Plus if my pet is on other medications for a chronic condition?

A: Official labeling specifically contraindicates use with piperazine preparations and advises caution with other cholinergic compounds. The product information does not list restrictive interactions with most other chronic medications, but it is important to review a pet's full list of current medications with a healthcare professional due to the potential for interactions.


Q: Does Dehinel Plus interact with flea and tick preventatives?

A: The regulatory documents list specific restrictions concerning piperazine compounds and general caution with other cholinergic compounds. There is no documented interaction or restriction specifically noted in official labeling regarding concurrent use with standard, non-cholinergic flea and tick prevention products.


Q: Is it safe to give Dehinel Plus to puppies?

A: Official product information confirms that the medication may be used in puppies that meet the minimum age and weight requirements, specifically those older than two weeks of age and weighing over 2 kg. Puppies often follow a more frequent dosing schedule.


Q: How long do the effects of one dose of Dehinel Plus last?

A: Official regulatory studies primarily focus on short-term efficacy, with follow-up assessments typically limited to one to two weeks post-treatment for faecal analysis. The recommended routine dosing schedule of every three months is set to maintain control against recurring parasite infections.


Q: Why is a follow-up dose of Dehinel Plus sometimes recommended?

A: The recommended dosing schedules often involve cyclical or repeated administration, such as giving the product every few weeks for young puppies. This repeated administration is intended to achieve continuous control by targeting any newly emerging parasites that may hatch from eggs after the initial dose.

How should Dehinel Plus be stored and disposed of?

How to Store and Dispose of Dehinel Plus

Storage Requirements

Official regulatory information states that Dehinel Plus Flavour Tablets for dogs does not require any special storage conditions for temperature or environment. The product must always be stored out of the sight and reach of children to prevent accidental exposure. Stability is maintained up to the labeled expiry date; the product must not be used after this date. Importantly, any part-used tablets must be discarded immediately to maintain product integrity and safety.


Disposal Instructions

Disposal of any unused veterinary medicinal product or waste materials must be carried out in accordance with local requirements. To protect the environment, the medicine should not be disposed of via wastewater or household waste. Collection programs, such as take-back schemes, should be used for the proper environmental disposal of expired or unused tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dehinel Plus found in:

A-Z Index: